

27th July, 2016

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, ("SEBI Regulations") of Financial Results (Standalone and Consolidated) for the quarter ended on 30th June, 2016.

In continuation to our letter dated 11th July, 2016 intimating about the Board meeting to be held on Wednesday, 27th July, 2016, we would like to inform that the Board meeting commenced at 03:00 pm and concluded at 06:00 pm, and it considered and approved the following:

1. Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results alongwith the limited review report of the Company for the quarter ended on 30th June, 2016 as per Regulation 33 of SEBI Regulations.

In terms of Regulation 47 of the SEBI Regulations, the Company will publish Unaudited Consolidated Financial Results for the quarter ended on 30th June, 2016. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.


2. Press Release on Financial Results including performance highlights as being submitted to the media.

The above is enclosed herewith for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26585090 www.torrentpharma.com

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF INTERIM FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF
TORRENT PHARMACEUTICALS LIMITED

1. We have audited the accompanying Statement of Standalone Financial Results of **TORRENT PHARMACEUTICALS LIMITED** ("the Company") for the Quarter ended June 30, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the related interim financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, the Statement:

Handwritten signature/initials


Deloitte Haskins & Sells

Chartered Accountants
19th Floor, Shapath-V
S. G. Highway
Ahmedabad - 380 015
Gujarat, India

Tel: +91 (079) 6682 7300
Fax: +91 (079) 6682 7400

- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the Quarter ended June 30, 2016.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm's Registration No. 117365W)



Hemendra L. Shah
Partner

(Membership No. 33590)

AHMEDABAD, 27 July, 2016







Torrent Pharmaceuticals Limited

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26585090 / 26583060 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website: www.torrentpharma.com; Email: investorservices@torrentpharma.com

PART I [Rs. in Crores except per share data]				
Statement of Standalone Audited Results for the Quarter and Year Ended 30-Jun-2016				
Particulars	Quarter ended			Year ended
	30-Jun-2016	31-Mar-2016	30-Jun-2015	31-Mar-2016
Income from operations				
Net Sales (net off excise duty)	1282	963	1810	5291
Other operating income	36	23	57	138
Total Income from operations (Net)	1318	986	1867	5429
Expenses				
Cost of materials consumed	342	242	264	1041
Purchases of stock-in-trade	50	49	47	192
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(20)	21	(12)	(50)
Employee benefits expense	179	157	136	572
Depreciation and amortisation expense	61	55	52	213
Other expenses	300	298	254	1034
Total expenses	912	822	741	3002
Profit from operations before other income, finance costs and exceptional items	406	164	1126	2427
Other income	49	37	76	293
Profit from ordinary activities before finance costs and exceptional items	455	201	1202	2720
Finance costs	48	38	53	180
Profit from ordinary activities after finance costs but before exceptional item	407	163	1149	2540
Exceptional items	-	-	-	193
Profit from ordinary activities before tax	407	163	1149	2347
Tax expense	70	39	310	605
Net profit for the period	337	124	839	1742
Other comprehensive income (after tax)	(5)	14	(42)	(2)
Total comprehensive income	332	138	797	1740
Paid-up equity share capital (Face value of Rs. 5 each)	85	85	85	85
Reserves excluding Revaluation Reserves				3622
Earnings per share (of Rs. 5/- each) (not annualised):				
Basic	19.95	7.33	49.59	102.99
Diluted	19.95	7.33	49.59	102.99




Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 27-Jul-2016. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The Financial results for the quarter ended 30-Jun-2016 are in compliance with Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. Consequently, result for the quarter ended 31-Mar-2016, 30-Jun-2015 and previous year ended 31-Mar-2016 have been restated to comply with Ind-AS to make them comparable.
- 3 The Company has entered into a binding agreement to acquire the Vizag API manufacturing unit of Hyderabad based Glochem Industries Limited as a going concern on a Slump sale basis. The transaction is subject to satisfaction of various Condition Precedent by both the parties.
- 4 The Company operates in a single segment i.e Generic Formulation Business and hence does not have any additional disclosure to be made under Ind-AS 108 - Operating Segments.
- 5 The company has commenced commercial production and dispatches from its Dahej SEZ facility in Gujarat with effect from 06-Apr-2016.
- 6 The listed Non Convertible Debentures of the company aggregating to Rs. 490 crores as on 30-Jun-2016 are secured by way of first pari passu charge created through mortgage on certain immovable & movable assets and identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 7 Audited reconciliations between net profit for the period reported and reserves as at 31-March-2016 under IGAAP (Previous GAAP) and Ind AS are as under:

Particulars	Profit Reconciliation			[Rs. in Crores]
	Quarter ended		Year ended	Reserve Reconciliation
	31-Mar-2016	30-Jun-2015	31-Mar-2016	Year ended 31-Mar-2016
Net Profit / Reserves as per IGAAP	121	830	1763	3601
Add / (Less) : Adjustments for GAAP Differences				
Effect of measuring investments at fair value through profit and loss	(3)	2	18	19
Effect of measuring Derivative contracts at Mark-to-Market value	(1)	(0)	(3)	0
Actuarial (gain)/loss on employee defined benefit plan recognized in Other Comprehensive Income	3	4	16	-
Borrowings measured at amortised cost & effect on finance cost	1	3	2	11
Effect of measuring investments at fair value through other comprehensive income	-	-	(53)	-
Amortization of Goodwill being reversed	2	2	8	8
Deferred Tax adjustments	1	(2)	(8)	(16)
Others	0	0	(1)	(1)
Net Profit before OCI / Reserves as per Ind AS	124	839	1742	3622

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat
Date : 27-Jul-2016



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TORRENT PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **TORRENT PHARMACEUTICALS LIMITED** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the Quarter ended June 30, 2016 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:

(1) Zao Torrent Pharma, (2) Torrent Pharma GmbH, (3) Heumann Pharma GmbH & Co. Generica KG, (4) Torrent Do Brasil Ltda., (5) Torrent Pharma Philippines Inc. (6) Torrent Pharma Inc., (7) Laboratories Torrent S.A. de C.V., (8) Torrent Australasia Pty Ltd., (9) Heunet Pharma GmbH, (10) Norispharm GmbH (11) Torrent Pharma (Thailand) Co. Limited, (12) Torrent Pharma S.R.L., (13) Torrent Pharma (UK) Limited, (14) Torrent Pharma (Sikkim), (15) Laboratories Torrent (Malaysia) Sdn. Bhd., (16) Torrent Pharma France S.A.S (17) Aptil Pharma Limited
4. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the

Deloitte Haskins & Sells

Chartered Accountants
19th Floor, Shapath-V
S. G. Highway
Ahmedabad - 380 015
Gujarat, India

Tel: +91 (079) 6682 7300
Fax: +91 (079) 6682 7400

aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm's Registration No. 117365W)



Hemendra L. Shah
Partner
(Membership No. 33590)

AHMEDABAD, 27 July, 2016






TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: + 91 79 26585090 / 26583060 Fax: + 91 79 2658100

CIN: L24230GJ1972PLC002126; Website: www.torrentpharma.com; Email: investorservices@torrentpharma.com

PART I					[Rs. in Crores except per share data]
Statement of Consolidated Results for the Quarter and Year Ended 30-Jun-2016					
Particulars	Quarter ended (Unaudited)			Year ended (Audited)	
	30-Jun-2016	31-Mar-2016	30-Jun-2015	31-Mar-2016	
Income from operations					
Net Sales (net of excise duty)	1507	1473	1886	6529	
Other operating income	38	26	61	147	
Total income from operations (net)	1545	1499	1947	6676	
Expenses					
Cost of materials consumed	343	242	264	1047	
Purchases of stock-in-trade	182	194	162	678	
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(88)	(25)	(8)	(148)	
Employee benefits expense	252	227	207	842	
Depreciation and amortisation expense	68	63	57	238	
Other expenses	419	374	410	1523	
Total expenses	1176	1075	1092	4180	
Profit from operations before other income, finance costs and exceptional items	369	424	855	2496	
Other income	26	24	75	225	
Profit from ordinary activities before finance costs and exceptional items	395	448	930	2721	
Finance costs	49	38	55	184	
Profit from ordinary activities after finance costs but before exceptional items	346	410	875	2537	
Exceptional items	-	-	-	194	
Profit from ordinary activities before tax	346	410	875	2343	
Tax expense	54	126	225	610	
Net Profit for the period	292	284	650	1733	
Share of profit/ (loss) of associates	-	-	-	-	
Minority Interest	0	0	0	0	
Net Profit after taxes, minority interest and share of profit/ (loss) of associates	292	284	650	1733	
Other Comprehensive Income (after tax)	(19)	(4)	(58)	(42)	
Total Comprehensive Income	273	280	592	1691	
Paid-up equity share capital (Face value of Rs. 5 each)	85	85	85	85	
Reserves excluding Revaluation Reserves				3409	
Earnings per share (of Rs. 5/- each) (not annualised):					
Basic	17.28	16.78	38.40	102.42	
Diluted	17.28	16.78	38.40	102.42	




Notes:

- 1 The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors in their respective meetings held on 27-Jul-2016. There is no qualification in the Auditors report on this statement of financial results.
- 2 The Financial results for the quarter ended 30-Jun-2016 are in compliance with Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. Consequently, result for the quarter ended 31-Mar-2016, 30-Jun-2015 and previous year ended 31-Mar-2016 have been restated to comply with Ind-AS to make them comparable.
- 3 The Company has entered into a binding agreement to acquire the Vizag API manufacturing unit of Hyderabad based Glochem Industries Limited as a going concern on a Slump sale basis. The transaction is subject to satisfaction of various Condition Precedent by both the parties.
- 4 The consolidated financial results include the financial results of Sixteen wholly owned subsidiaries and one partnership firm with that of the Company.
- 5 The Company operates in a single segment i.e Generic Formulation Business and hence does not have any additional disclosure to be made under Ind-AS 108 - Operating Segments.
- 6 The Company has commenced commercial production and dispatches from its Dahej SEZ facility in Gujarat with effect from 06-Apr-2016.
- 7 The listed Non Convertible Debentures of the company aggregating to Rs. 490 crores as on 30-Jun-2016 are secured by way of first pari passu charge created through mortgage on certain immovable & movable assets and identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 8 Reconciliation of net profit for the period reported and reserves as at 31-March-2016 under IGAAP (Previous GAAP) and Ind AS are as under:


[Rs. in Crores]

Particulars	Profit Reconciliation			Reserve Reconciliation
	Quarter ended (Unaudited)		Year ended (Audited)	Year ended (Audited)
	31-Mar-2016	30-Jun-2015	31-Mar-2016	31-Mar-2016
Net Profit / Reserves as per IGAAP	357	449	1722	3304
Add / (Less) : Adjustments for GAAP Differences				
Effect of measuring investments at fair value through profit and loss	(3)	2	18	19
Effect of measuring Derivative contracts at Mark-to-Market value	3	6	(9)	(1)
Actuarial (gain)/loss on employee defined benefit plan recognized in Other Comprehensive Income	3	3	14	-
Borrowings measured at amortised cost & effect on finance cost	0	3	2	11
Effect of measuring investments at fair value through other comprehensive income	-	-	(53)	-
Amortization of Goodwill being reversed	2	2	8	8
Deferred Tax adjustments	(78)	185	31	69
Others	-	-	-	(1)
Net Profit before OCI / Reserves as per Ind AS	284	650	1733	3409

For TORRENT PHARMACEUTICALS LIMITED


SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat
Date : 27-Jul-2016



Torrent Pharma announces Q1 FY 2016-17 Results.

July 27th 2016

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th June 2016.

Quarterly Financials

- For Q1 FY 2016-17 revenues were at Rs. 1,545 crores as against Rs. 1,947 crores during the same period last year.
- EBIDTA for Q1 FY 2016-17 was at Rs. 462 crores as against Rs. 985 crores during the same period last year.
- PAT for Q1 2016-17 was at Rs. 292 crores as against Rs.650 crores during the same period last year.
- Previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition.
- Research and development spend during the quarter was up by 62%, from Rs. 56 crores in the same period previous year to Rs. 91 crores.

Q1 PERFORMANCE HIGHLIGHTS**India Business**

- Domestic formulation business recorded revenues of Rs. 504 crores for Q1 FY 2016-17 vs Rs. 491 crores showing 3% growth for the same period last year. Discontinuance of certain promotional schemes and hygiene initiatives has impacted the business in short term however it will have positive impact in long term.

Brazil Business

- Brazilian business recorded revenues of Rs. 167 crores for Q1 FY 2016-17 vs Rs. 138 crores for the same period last year, showing 21% growth. The growth in Real is 31%.

USA

- US business recorded revenues of Rs. 434 crores for Q1 FY 2016-17 vs Rs. 888 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.



Germany

- German business recorded revenues of Rs. 187 crores for Q1 FY 2016-17 vs Rs. 157 crores for the same period last year.

Financial Highlights	Q1 FY 16-17	Q1 FY 15-16	Growth
Revenues	1,545	1,947	-21%
EBITDA	462	985	-53%
% Revenues	30%	51%	
PBT (after Exceptional Items)	346	875	-60%
% Revenues	22%	45%	
PAT (after Exceptional Items)	292	650	-55%
% Revenues	19%	33%	
EPS	17.3	38.4	-55%

All amounts in ₹ crs except per share data

About Torrent Pharma

Torrent Pharma, with annual revenues of more than Rs. 6600 crores is the flagship Company of the Rs. 18,300 crore Torrent Group.

Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Center, employing almost 900 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim, Dahej and Pithampur have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.

